ESMO 2024

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

4-year update of Riboclib in EBC - can we avoid chemo?

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

New updates from the innovative I-SPY program

Hypofractionation in early breast cancer

Survival benefit reported with Pembro

Endocrine therapy in triple-positive premenopausal patients

Physical exercise and oncological outcome

Registry data from France - no break in endocrine therapy in young patients

Compliance is everything

Overall survival advantage for Pembrolizumab in early TNBC

Survival data from WSG-TP-II

4-year landmark data

Evaluation of the patient collective under 40 years

Ribociclib in younger patients

Update on NATALEE in young patients

Update on NATALEE in young patients

Physical exercise and oncological outcome

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

De-Escalation in the metastatic setting

PIK3CA is not a vaild pathway in triple-negative breast cancer

Brain imaging screening in MBC patients

No benefit of Akt-inhibition in mTNBC

Highlights of ESMO 2024

New approaches to treat 1L patients mTNBC

Akt-inhibition works with HR+ but not with mTNBC

Keep the patients trained!

TILs and overall survival in the shortHER trial

Brain imaging screening in MBC patients

PIK3CA is not a vaild pathway in triple-negative breast cancer

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

TILs e sopravvivenza nello studio shortHER

Punti salienti di ESMO 2024

New first choice treatment for patients with brain metastases?

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

ctDNA data and clinical efficacy of SG

T-Dxd in patients with and without brain metastases

Optimization treatment with ADCs in endocrine therapy

Efficacy of T-Dxd in patients with brain metastasis

Soon no chemotherapy for triplenegative mBC

HER3- DXd in the ICARUS Breast-01 study

Her3-Dxd - new application area for ADCs

Endocrine-based therapy in combination with dual blockade

Study impression in HR+/HER2- mBC progressing after two lines of therapy

High sensitivity testing as outcome predictor for T-DXD in mBC

Outstanding efficacy of T-Dxd in CNS meastases

T-Dxd in BrainMets

Primary results of DB-12

Primary systematic treatment of active brain metastases

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Endocrine resistance to CDK4/6 inhibitors

CTCs as surrogate markers for endocrine therapy

Screening for brain metastases – what do doctors and patients think about it?

Niraparib in ovarian cancer without survival benefit

The importance of markers for patient management

Overview on the perioperative treatment landscape

Significant CNS protection by osimertinib

Neoadjuvant vs. Perioperative

ctDNA - a promising new biomarker in early lung cancer

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

BR31: The first negative adjuvant study in resected NSCLC

Negative adjuvant CPI trial

Perioperative IO Therapy - adjuvant necessary?

Should we move away from adjuvant immunotherapy?

Getting rid of it will save your life!

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

Eliminarlo potrebbe salvarti la vita

Should we move away from adjuvant immunotherapy?

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Update on genetic alterations - ALK / ROS / KRAS / BRAF

New 1st line treatment opportunities in advanced stage NSCLC

Pieces of evidence in the EGFR domain

Patterns of resistance in MARIPOSA trial

NVL-520 for ROS alteration - already best in class?

Optimizing the dose of immunotherapy

Half of the dose - same activity: provocative findings from NVALT-30

The next generation of ROS inhibitors

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

Two sometimes may be better than one!

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

RELATIVITY-104: efficacy of anti immunotherapy

Adding anti-LAG-3 doesn't seem to being worth it

Survival Data with Amivantamab for EGFR Alteration

Sustained OS at 2nd interim analysis in MARIPOSA-2

Early mechanisms of resistance from MARIPOSA

4th generation with ALK-alterations

NVL-655: a promising new ALK inhibitor

1st line encorafenib + binimetinib: combination is very active but PFS very different

Second interim analysis of MARIPOSA-2

Quality of life with Telisotuzumab in LUMINOSITY

The next generation of ALK inhibitors

Bispecific antibodies better than ADCs?

Optimizing the dose of immunotherapy

Second interim analysis of MARIPOSA-2

2 a volte sono meglio di uno

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

Aggiungere l'anti-LAG-3 non sembra valerne la pena

Quality of life with Telisotuzumab in LUMINOSITY

RELATIVITY-104: efficacy of anti immunotherapy

Patterns of resistance in MARIPOSA trial

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

New data on SCLC and mesothelioma

Subset analysis from ADRIATIC

New standard of care in LS-SCLC

Neuer Behandlungsstandard beim LS-SCLC

Is the radiologist redundant in mesothelioma RECIST measurements

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

IO in mCRPC: Let's move on to the next substance?!

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

Metformin in mHSPC

Radium and enzalutamide in mCRPC - final results

LuPSMA moves UpFront

Not a Patch on ADT?

Did CONTACT make any contact?

Radium-223 an option again?

New hormone therapy for mCRPC

Was it a splash or was it a splish?

PSMA-radioligand - the first study of its kind

Immunotherapy for prostate cancer

Darolutamide in mHSPC

Upfronts in personal

Molecular analysis from PEACE-1

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

We come in PEACE

New PSMA-ligand

Radium and enzalutamide in mCRPC - final results

New PSMA-ligand

Molecular analysis from PEACE-1

PSMA-radioligand - the first study of its kind

Establishing ICI as standard of care in RCC

IO after IO – is there a role for sequential immunotherapy in RCC?

Where is the right place for HIF inhibitors in advanced RCC therapy?

Microbiome transplantation in RCC – how to tailor this therapy for our patients

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

Stool transplantation is the shit

CPI - modification / prediction - fact or fantasy?

mRCC ≥ 1L? News on intensification?

Sequencing checkpoint inhibitors - the story is over

FMT in a novel setting

Ipi-Nivo in nccRCC

Updated survival results

Opening a new way of treatment in MIBC

SUNNIFORECAST - rain or shine?

Treating nccRCC - Nivo/Ipi as a new potential option

The role of sequencing therapy in RCC

Immunotherapy for nccRCC

TKI monotherapy remains standard in 2ndL

IO therapy is standard for nccRCC

New SOC for non-cc-RCC?

My view on SUNNIFORECAST

HIF-2a inhibitors are on their way

Sequencing checkpoint inhibitors - the story is over

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Encouraging data - but we need more data!

Biomarkers in Bladder cancer - the road to individualized therapy

Chemo + IO in the perioperative setting - new standard of care

New standard: perioperative MIBC-NIAGARA

Practice changing new data in Bladder cancer at ESMO24

Pretzel therapy for superficial UC

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

Value of ctDNA

mUC - new ADC's?

EV + Pembro is broadly effective

New data on ADCs in bladder cancer

A new way to give chemo for patients who are ineligible for neoadj therapy

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

Is intravesical therapy as easy as baking a pretzel?

NIAGARA sets new standard

Practice changing new data in Bladder cancer at ESMO24

A new way to give chemo for patients who are ineligible for neoadj therapy

Nuevos datos sobre las ADC en el cáncer de vejiga